Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria

다국어 초록 (Multilingual Abstract)

Background: To evaluate the changes in cardiovascular risk markers including pulse wave velocity (PWV), microalbuminuria, inflammatory cytokines, and adhesion molecules after treatment with beraprost sodium (BPS) in patients with diabetic nephropathyMethods: This was a multicenter, prospective, randomized, double-blind, placebo-controlled trial. Type 2 diabetes mellitus patientswith microalbuminuria were included. The primary endpoints were changes in microalbuminuria in spot urine and PWV after BPSor placebo (PCB) treatment for 24 weeks. The secondary endpoints were changes in clinical and metabolic parameters.
Results: A total of 52 patients completed the 24-week trial. Changes in PWV were not different significantly in the BPS and PCBgroups (right, P=0.16; left, P=0.11). Changes in microalbuminuria were 14.2±157.0 and 34.5±146.6 (μg/mg Cr) in the BPS andPCB groups, respectively (P=0.63). Subgroup analysis in the high blood pressure (BP) group (baseline systolic BP >120 mm Hgand diastolic BP >80 mm Hg), showed that microalbuminuria decreased by –47.6 in the BPS group compared with an increase by116.4 (μg/mg Cr) in the PCB group (P=0.04). Also, in the large waist circumference group (>95 cm), microalbuminuria decreasedsignificantly in the BPS group (P=0.04).
Conclusion: Short-term treatment of BPS for patients with diabetic nephropathy did not show significant improvement in variouscardiovascular risk factors. However, BPS significantly decreased microalbuminuria in study subjects with higher cardiovascularrisk such as high BP or large waist circumference

참고문헌 (Reference)

1 Makino H, "Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy" 68 : 45-55, 1993

2 Nakayama T, "The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction" 70 : 491-494, 2004

3 Shin S, "The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial" 15 : 185-188, 2013

4 Mauer SM, "Structural-functional relationships in diabetic nephropathy" 74 : 1143-1155, 1984

5 Fujita T, "PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency" 65 : 223-227, 2001

6 Grassi G, "Obesity and vascular stiffness : when body fat has an adverse impact on arterial dynamics" 23 : 1789-1791, 2005

7 Lehmann ED, "Non-invasive assessment of cardiovascular disease in diabetes mellitus" 35 (35): SI14-SI19, 1997

8 Kim HK, "Impaired fasting glucose and risk of cardiovascular disease in Korean men and women : the Korean Heart Study" 36 : 328-335, 2013

9 Arima S, "Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles" 45 : 650-658, 1994

10 Goya K, "Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1level in patients with type 2 diabetes mellitus" 52 : 192-198, 2003

11 Wang LN, "Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes" 73 : 637-643, 1996

12 Chapleau CE, "Effects of prostacyclin on the canine isolated basilar artery" 17 : 573-580, 1979

13 Villa E, "Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy" 10 : 202-208, 1997

14 Koh E, "Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells" 20 : 242-252, 1993

15 Guan J, "Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy" 13 : 4154-4158, 2014

16 Owada A, "Effect of long-term administration of prostaglandin I(2)in incipient diabetic nephropathy" 92 : 788-796, 2002

17 Cecelja M, "Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension : a systematic review" 54 : 1328-1336, 2009

18 Yamashita T, "Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats" 57 : 149-161, 2002

19 Shima A, "Beraprost sodium protects against diabetic nephropathy in patients with arteriosclerosis obliterans: a prospective, randomized, open-label study" 82 : 84-91, 2015

20 Melian EB, "Beraprost : a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension" 62 : 107-133, 2002

21 Nakayama T, "Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction" 76 : 309-314, 2007

22 Amar J, "Arterial stiffness and cardiovascular risk factors in a population-based study" 19 : 381-387, 2001

23 Cruickshank K, "Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?" 106 : 2085-2090, 2002

24 Watanabe M, "Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium" 30 : 1-11, 2009